The antidiabetic effect of ginsenoside Rb2 via activation of AMPK

• Published in: Archives of pharmacal research Vol. 34; no. 7; pp. 1201 - 1208
• Main Authors: Lee, Kyoung-Tae, Jung, Tae Woo, Lee, Hak-Ju, Kim, Seul-Gi, Shin, Yu-Su, Whang, Wan-Kyunn
• Format: Journal Article
• Language: English
• Published: Heidelberg Pharmaceutical Society of Korea 01.07.2011; 대한약학회
• Subjects: AMP-Activated Protein Kinases - metabolism; Animals; Diabetes Mellitus, Type 2 - drug therapy; Gene Silencing - drug effects; Ginsenosides - metabolism; Ginsenosides - pharmacology; Gluconeogenesis - drug effects; Glucose - analysis; Glucose - biosynthesis; Hepatocytes - drug effects; Hypoglycemic Agents - metabolism; Hypoglycemic Agents - pharmacology; Liver - drug effects; Liver - metabolism; Medicine; Pharmacology/Toxicology; Pharmacy; Phosphorylation - drug effects; Protein Tyrosine Phosphatase, Non-Receptor Type 6 - drug effects; Rats; RNA - analysis; Transfection; 약학; H4IIE cells; AMPK; SHP; Rb2
• ISSN: 0253-6269; 1976-3786
• DOI: 10.1007/s12272-011-0719-6

Ginsenosides, which are active compounds found in ginseng ( Panax ginseng ), are used as antidiabetic treatments. The aim of this study was to determine whether Rb2, a type of ginsenoside, regulates hepatic gluconeogenesis through AMP-activated protein kinase (AMPK) and the orphan nuclear receptor small heterodimer partner (SHP) in hyperlipidemic conditions used as an in vitro model of type 2 diabetes. Considering these results, we concluded that Rb2 may inhibit palmitate-induced gluconeogenesis via AMPK-induced SHP by relieving ER stress, a cause of gluconeogenesis.